Your browser doesn't support javascript.
loading
MRP4 Modulation of the Guanylate Cyclase-C/cGMP Pathway: Effects on Linaclotide-Induced Electrolyte Secretion and cGMP Efflux.
Tchernychev, Boris; Ge, Pei; Kessler, Marco M; Solinga, Robert M; Wachtel, Derek; Tobin, Jenny V; Thomas, Sara R; Lunte, Craig E; Fretzen, Angelika; Hannig, Gerhard; Bryant, Alexander P; Kurtz, Caroline B; Currie, Mark G; Silos-Santiago, Inmaculada.
Afiliação
  • Tchernychev B; Ironwood Pharmaceuticals, Cambridge, Massachusetts (B.T., P.G., M.M.K., R.M.S., D.W., J.V.T., A.F., G.H., A.P.B., C.B.K., M.G.C., I.S.-S.); and Ralph N. Adams Institute for Bioanalytical Chemistry, Department of Chemistry, University of Kansas, Lawrence, Kansas (S.R.T., C.E.L.).
  • Ge P; Ironwood Pharmaceuticals, Cambridge, Massachusetts (B.T., P.G., M.M.K., R.M.S., D.W., J.V.T., A.F., G.H., A.P.B., C.B.K., M.G.C., I.S.-S.); and Ralph N. Adams Institute for Bioanalytical Chemistry, Department of Chemistry, University of Kansas, Lawrence, Kansas (S.R.T., C.E.L.).
  • Kessler MM; Ironwood Pharmaceuticals, Cambridge, Massachusetts (B.T., P.G., M.M.K., R.M.S., D.W., J.V.T., A.F., G.H., A.P.B., C.B.K., M.G.C., I.S.-S.); and Ralph N. Adams Institute for Bioanalytical Chemistry, Department of Chemistry, University of Kansas, Lawrence, Kansas (S.R.T., C.E.L.).
  • Solinga RM; Ironwood Pharmaceuticals, Cambridge, Massachusetts (B.T., P.G., M.M.K., R.M.S., D.W., J.V.T., A.F., G.H., A.P.B., C.B.K., M.G.C., I.S.-S.); and Ralph N. Adams Institute for Bioanalytical Chemistry, Department of Chemistry, University of Kansas, Lawrence, Kansas (S.R.T., C.E.L.).
  • Wachtel D; Ironwood Pharmaceuticals, Cambridge, Massachusetts (B.T., P.G., M.M.K., R.M.S., D.W., J.V.T., A.F., G.H., A.P.B., C.B.K., M.G.C., I.S.-S.); and Ralph N. Adams Institute for Bioanalytical Chemistry, Department of Chemistry, University of Kansas, Lawrence, Kansas (S.R.T., C.E.L.).
  • Tobin JV; Ironwood Pharmaceuticals, Cambridge, Massachusetts (B.T., P.G., M.M.K., R.M.S., D.W., J.V.T., A.F., G.H., A.P.B., C.B.K., M.G.C., I.S.-S.); and Ralph N. Adams Institute for Bioanalytical Chemistry, Department of Chemistry, University of Kansas, Lawrence, Kansas (S.R.T., C.E.L.).
  • Thomas SR; Ironwood Pharmaceuticals, Cambridge, Massachusetts (B.T., P.G., M.M.K., R.M.S., D.W., J.V.T., A.F., G.H., A.P.B., C.B.K., M.G.C., I.S.-S.); and Ralph N. Adams Institute for Bioanalytical Chemistry, Department of Chemistry, University of Kansas, Lawrence, Kansas (S.R.T., C.E.L.).
  • Lunte CE; Ironwood Pharmaceuticals, Cambridge, Massachusetts (B.T., P.G., M.M.K., R.M.S., D.W., J.V.T., A.F., G.H., A.P.B., C.B.K., M.G.C., I.S.-S.); and Ralph N. Adams Institute for Bioanalytical Chemistry, Department of Chemistry, University of Kansas, Lawrence, Kansas (S.R.T., C.E.L.).
  • Fretzen A; Ironwood Pharmaceuticals, Cambridge, Massachusetts (B.T., P.G., M.M.K., R.M.S., D.W., J.V.T., A.F., G.H., A.P.B., C.B.K., M.G.C., I.S.-S.); and Ralph N. Adams Institute for Bioanalytical Chemistry, Department of Chemistry, University of Kansas, Lawrence, Kansas (S.R.T., C.E.L.).
  • Hannig G; Ironwood Pharmaceuticals, Cambridge, Massachusetts (B.T., P.G., M.M.K., R.M.S., D.W., J.V.T., A.F., G.H., A.P.B., C.B.K., M.G.C., I.S.-S.); and Ralph N. Adams Institute for Bioanalytical Chemistry, Department of Chemistry, University of Kansas, Lawrence, Kansas (S.R.T., C.E.L.).
  • Bryant AP; Ironwood Pharmaceuticals, Cambridge, Massachusetts (B.T., P.G., M.M.K., R.M.S., D.W., J.V.T., A.F., G.H., A.P.B., C.B.K., M.G.C., I.S.-S.); and Ralph N. Adams Institute for Bioanalytical Chemistry, Department of Chemistry, University of Kansas, Lawrence, Kansas (S.R.T., C.E.L.).
  • Kurtz CB; Ironwood Pharmaceuticals, Cambridge, Massachusetts (B.T., P.G., M.M.K., R.M.S., D.W., J.V.T., A.F., G.H., A.P.B., C.B.K., M.G.C., I.S.-S.); and Ralph N. Adams Institute for Bioanalytical Chemistry, Department of Chemistry, University of Kansas, Lawrence, Kansas (S.R.T., C.E.L.).
  • Currie MG; Ironwood Pharmaceuticals, Cambridge, Massachusetts (B.T., P.G., M.M.K., R.M.S., D.W., J.V.T., A.F., G.H., A.P.B., C.B.K., M.G.C., I.S.-S.); and Ralph N. Adams Institute for Bioanalytical Chemistry, Department of Chemistry, University of Kansas, Lawrence, Kansas (S.R.T., C.E.L.).
  • Silos-Santiago I; Ironwood Pharmaceuticals, Cambridge, Massachusetts (B.T., P.G., M.M.K., R.M.S., D.W., J.V.T., A.F., G.H., A.P.B., C.B.K., M.G.C., I.S.-S.); and Ralph N. Adams Institute for Bioanalytical Chemistry, Department of Chemistry, University of Kansas, Lawrence, Kansas (S.R.T., C.E.L.) isilos-santiago@ironw
J Pharmacol Exp Ther ; 355(1): 48-56, 2015 Oct.
Article em En | MEDLINE | ID: mdl-26216942
ABSTRACT
MRP4 mediates the efflux of cGMP and cAMP and acts as an important regulator of these secondary messengers, thereby affecting signaling events mediated by cGMP and cAMP. Immunofluorescence staining showed high MRP4 expression localized predominantly in the apical membrane of rat colonic epithelium. In vitro studies were performed using a rat colonic mucosal layer mounted in an Ussing chamber. Linaclotide activation of the guanylate cyclase-C (GC-C)/cGMP pathway induced a concentration-dependent increase in transepithelial ion current [short-circuit current (Isc)] across rat colonic mucosa (EC50 9.2 nM). Pretreatment of colonic mucosa with the specific MRP4 inhibitor MK571 potentiated linaclotide-induced electrolyte secretion and augmented linaclotide-stimulated intracellular cGMP accumulation. Notably, pretreatment with the phosphodiesterase 5 inhibitor sildenafil increased basal Isc, but had no amplifying effect on linaclotide-induced Isc. MRP4 inhibition selectively affected the activation phase, but not the deactivation phase, of linaclotide. In contrast, incubation with a GC-C/Fc chimera binding to linaclotide abrogated linaclotide-induced Isc, returning to baseline. Furthermore, linaclotide activation of GC-C induced cGMP secretion from the apical and basolateral membranes of colonic epithelium. MRP4 inhibition blocked cGMP efflux from the apical membrane, but not the basolateral membrane. These data reveal a novel, previously unrecognized mechanism that functionally couples GC-C-induced luminal electrolyte transport and cGMP secretion to spatially restricted, compartmentalized regulation by MRP4 at the apical membrane of intestinal epithelium. These findings have important implications for gastrointestinal disorders with symptoms associated with dysregulated fluid homeostasis, such as irritable bowel syndrome with constipation, chronic idiopathic constipation, and secretory diarrhea.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Peptídeos / Propionatos / Quinolinas / Transdução de Sinais / Receptores de Peptídeos / GMP Cíclico / Proteínas Associadas à Resistência a Múltiplos Medicamentos / Eletrólitos / Receptores Acoplados a Guanilato Ciclase Limite: Animals Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Peptídeos / Propionatos / Quinolinas / Transdução de Sinais / Receptores de Peptídeos / GMP Cíclico / Proteínas Associadas à Resistência a Múltiplos Medicamentos / Eletrólitos / Receptores Acoplados a Guanilato Ciclase Limite: Animals Idioma: En Ano de publicação: 2015 Tipo de documento: Article